PE20141381A1 - Terapia de combinacion que comprende un inhibidor de cdk4/6 y un inhibidor de pi3k para el uso en el tratamiento de cancer - Google Patents
Terapia de combinacion que comprende un inhibidor de cdk4/6 y un inhibidor de pi3k para el uso en el tratamiento de cancerInfo
- Publication number
- PE20141381A1 PE20141381A1 PE2013002911A PE2013002911A PE20141381A1 PE 20141381 A1 PE20141381 A1 PE 20141381A1 PE 2013002911 A PE2013002911 A PE 2013002911A PE 2013002911 A PE2013002911 A PE 2013002911A PE 20141381 A1 PE20141381 A1 PE 20141381A1
- Authority
- PE
- Peru
- Prior art keywords
- inhibitor
- cancer
- cdk4
- treatment
- combination therapy
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
SE REFIERE A UNA COMBINACION QUE COMPRENDE: A) UN PRIMER AGENTE QUE ES UN INHIBIDOR DE CINASA 4 DEPENDIENTE DE CICLINA O CINASA 6 DEPENDIENTE DE CICLINA (CDK4/6) Y B) UN SEGUNDO AGENTE QUE ES UN INHIBIDOR DE PI3CINASA. DICHA COMBINACION ES UTIL PARA EL TRATAMIENTO DE CANCER DE MAMA, SARCOMAS, CANCER GASTRICO, MELANOMA, LEUCEMIA, CANCER DE PROSTATA
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201161503642P | 2011-07-01 | 2011-07-01 |
Publications (1)
Publication Number | Publication Date |
---|---|
PE20141381A1 true PE20141381A1 (es) | 2014-10-21 |
Family
ID=46513871
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PE2013002911A PE20141381A1 (es) | 2011-07-01 | 2012-07-02 | Terapia de combinacion que comprende un inhibidor de cdk4/6 y un inhibidor de pi3k para el uso en el tratamiento de cancer |
Country Status (22)
Country | Link |
---|---|
US (2) | US9271988B2 (es) |
EP (1) | EP2726074B1 (es) |
JP (2) | JP5832647B2 (es) |
KR (1) | KR20140040770A (es) |
CN (1) | CN103635189B (es) |
AU (3) | AU2012279117A1 (es) |
BR (1) | BR112013033940A2 (es) |
CA (1) | CA2840754A1 (es) |
CL (1) | CL2013003805A1 (es) |
CO (1) | CO6842016A2 (es) |
EA (1) | EA030465B1 (es) |
ES (1) | ES2676180T3 (es) |
GT (1) | GT201300320A (es) |
IL (1) | IL229876B (es) |
MA (1) | MA35210B1 (es) |
MX (1) | MX359406B (es) |
MY (1) | MY161237A (es) |
PE (1) | PE20141381A1 (es) |
TN (1) | TN2013000508A1 (es) |
UA (1) | UA114178C2 (es) |
WO (1) | WO2013006532A1 (es) |
ZA (1) | ZA201309241B (es) |
Families Citing this family (30)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP5869222B2 (ja) | 2008-01-04 | 2016-02-24 | インテリカイン, エルエルシー | 特定の化学的実体、組成物および方法 |
US8193182B2 (en) | 2008-01-04 | 2012-06-05 | Intellikine, Inc. | Substituted isoquinolin-1(2H)-ones, and methods of use thereof |
UA115767C2 (uk) | 2011-01-10 | 2017-12-26 | Інфініті Фармасьютікалз, Інк. | Способи отримання ізохінолінонів і тверді форми ізохінолінонів |
MY161237A (en) * | 2011-07-01 | 2017-04-14 | Novartis Ag | Combination therapy comprising a cdk4/6 inhibitor and a p13k inhibitor for use in the treatment of cancer |
CA2865993A1 (en) * | 2012-03-30 | 2013-10-03 | Novartis Ag | Compounds for use in the treatment of neuroblastoma, ewing's sarcoma or rhabdomyosarcoma |
US8828998B2 (en) | 2012-06-25 | 2014-09-09 | Infinity Pharmaceuticals, Inc. | Treatment of lupus, fibrotic conditions, and inflammatory myopathies and other disorders using PI3 kinase inhibitors |
AU2013296237B2 (en) | 2012-08-03 | 2019-05-16 | Foundation Medicine, Inc. | Human papilloma virus as predictor of cancer prognosis |
EP2742940B1 (en) | 2012-12-13 | 2017-07-26 | IP Gesellschaft für Management mbH | Fumarate salt of (R)-3-(6-(4-methylphenyl)-pyridin-3-yloxy)-l-aza-bicyclo-[2.2.2]octane for adminstration once daily, twice daily or thrice daily |
EP2967050A4 (en) | 2013-03-15 | 2016-09-28 | G1 Therapeutics Inc | HIGH-ACTIVE ANTINEOPLASTIC AND ANTIPROLIFERATIVE AGENTS |
SI2968290T1 (sl) | 2013-03-15 | 2020-02-28 | G1 Therapeutics, Inc., | Prehodna zaščita normalnih celic med kemoterapijo |
EP4005573A1 (en) * | 2013-08-14 | 2022-06-01 | Novartis AG | Combination therapy for the treatment of cancer |
US20150320755A1 (en) | 2014-04-16 | 2015-11-12 | Infinity Pharmaceuticals, Inc. | Combination therapies |
WO2015160986A2 (en) | 2014-04-16 | 2015-10-22 | Infinity Pharmaceuticals, Inc. | Combination therapies |
US20150297608A1 (en) | 2014-04-17 | 2015-10-22 | G1 Therapeutics, Inc. | Tricyclic Lactams for Use as Anti-Neoplastic and Anti-Proliferative Agents |
WO2016040858A1 (en) | 2014-09-12 | 2016-03-17 | G1 Therapeutics, Inc. | Combinations and dosing regimes to treat rb-positive tumors |
WO2016040848A1 (en) | 2014-09-12 | 2016-03-17 | G1 Therapeutics, Inc. | Treatment of rb-negative tumors using topoisomerase inhibitors in combination with cyclin dependent kinase 4/6 inhibitors |
PE20181021A1 (es) | 2015-07-02 | 2018-06-27 | Hoffmann La Roche | Compuestos de benzoxacepina oxazolidinona y metodos de uso |
WO2017001658A1 (en) | 2015-07-02 | 2017-01-05 | F. Hoffmann-La Roche Ag | Benzoxazepin oxazolidinone compounds and methods of use |
US10328066B2 (en) | 2015-08-28 | 2019-06-25 | Novartis Ag | Pharmaceutical combination comprising the PI3K inhibitor alpelisib and the CDK4/6 inhibitor ribociclib, and the use thereof in the treatment/prevention of cancer |
WO2017172734A1 (en) | 2016-03-29 | 2017-10-05 | Mayo Foundation For Medical Education And Research | Treating cancer metastasis |
KR20190033526A (ko) | 2016-06-24 | 2019-03-29 | 인피니티 파마슈티칼스, 인코포레이티드 | 병용 요법 |
WO2018017410A1 (en) | 2016-07-22 | 2018-01-25 | Eli Lilly And Company | Combination therapy of abemaciclib and a pi3 kinase/mtor dual inhibitor for use in the treatment of breast cancer |
WO2018081211A1 (en) * | 2016-10-26 | 2018-05-03 | Li George Y | Deuterated 7-cyclopentyl-n, n-dimethyl-2-((5-(piperazin-1-yl)pyridin-2-yl)amino)-7h-pyrrolo[2,3-d]pyrimdine-6-carboxamide |
KR20240023676A (ko) | 2016-12-05 | 2024-02-22 | 쥐원 쎄라퓨틱스, 인크. | 화학요법 레지멘 동안의 면역 반응의 보존 |
US11395821B2 (en) | 2017-01-30 | 2022-07-26 | G1 Therapeutics, Inc. | Treatment of EGFR-driven cancer with fewer side effects |
AU2019205821B2 (en) | 2018-01-08 | 2024-07-18 | G1 Therapeutics, Inc. | G1T38 superior dosage regimes |
ES2965632T3 (es) * | 2018-03-05 | 2024-04-16 | Klinikum Rechts Der Isar Der Technischen Univ Muenchen | Tratamiento de tumores mediante una combinación de un adenovirus oncolítico y un inhibidor de CDK4/6 |
CN111184863B (zh) * | 2018-11-15 | 2023-06-16 | 江苏恒瑞医药股份有限公司 | 酪氨酸激酶抑制剂、cdk4/6抑制剂、serd联合在制备治疗肿瘤的药物中的用途 |
US10988479B1 (en) | 2020-06-15 | 2021-04-27 | G1 Therapeutics, Inc. | Morphic forms of trilaciclib and methods of manufacture thereof |
KR20230007945A (ko) * | 2021-07-06 | 2023-01-13 | 국립암센터 | Cdk4/6 억제제 및 삼환계 항우울제를 포함하는 암의 예방 또는 치료를 위한 약학적 조성물 |
Family Cites Families (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8673924B2 (en) * | 2002-09-04 | 2014-03-18 | Merck Sharp & Dohme Corp. | Substituted pyrazolo[1,5-a]pyrimidines as cyclin dependent kinase inhibitors |
US7196078B2 (en) * | 2002-09-04 | 2007-03-27 | Schering Corpoartion | Trisubstituted and tetrasubstituted pyrazolopyrimidines as cyclin dependent kinase inhibitors |
ATE527250T1 (de) | 2002-11-21 | 2011-10-15 | Novartis Ag | 2,4,6-trisubstituierten pyrimidinen als phosphotidylinositol (pi) 3-kinase inhibitoren und deren verwendung zur behandlung von krebs |
TW200519106A (en) | 2003-05-02 | 2005-06-16 | Novartis Ag | Organic compounds |
GB0510390D0 (en) | 2005-05-20 | 2005-06-29 | Novartis Ag | Organic compounds |
JO2660B1 (en) * | 2006-01-20 | 2012-06-17 | نوفارتيس ايه جي | Pi-3 inhibitors and methods of use |
JO3235B1 (ar) | 2006-05-26 | 2018-03-08 | Astex Therapeutics Ltd | مركبات بيررولوبيريميدين و استعمالاتها |
AR070127A1 (es) | 2008-01-11 | 2010-03-17 | Novartis Ag | Pirrolo - pirimidinas y pirrolo -piridinas |
JP5323095B2 (ja) | 2008-02-06 | 2013-10-23 | ノバルティス アーゲー | ピロロ[2,3−d]ピリミジンおよびそのチロシンキナーゼ阻害剤としての使用 |
ES2522346T3 (es) | 2008-08-22 | 2014-11-14 | Novartis Ag | Compuestos de pirrolopirimidina como inhibidores de CDK |
UA104147C2 (uk) * | 2008-09-10 | 2014-01-10 | Новартис Аг | Похідна піролідиндикарбонової кислоти та її застосування у лікуванні проліферативних захворювань |
UY33227A (es) | 2010-02-19 | 2011-09-30 | Novartis Ag | Compuestos de pirrolopirimidina como inhibidores de la cdk4/6 |
CN104945373A (zh) | 2010-10-01 | 2015-09-30 | 诺华有限公司 | 制造嘧啶衍生物的方法 |
AR083797A1 (es) | 2010-11-10 | 2013-03-20 | Novartis Ag | Succinato de dimetil-amida del acido 7-ciclopentil-2-(5-piperazin-1-il-piridin-2-il-amino)-7h-pirrolo-[2,3-d]pirimidin-6-carboxilico, proceso para prepararla, intermediarios de dicha sintesis y proceso de preparacion de los mismos |
MY161237A (en) * | 2011-07-01 | 2017-04-14 | Novartis Ag | Combination therapy comprising a cdk4/6 inhibitor and a p13k inhibitor for use in the treatment of cancer |
US9408847B2 (en) * | 2012-11-28 | 2016-08-09 | Novartis Ag | Combination therapy |
-
2012
- 2012-07-02 MY MYPI2013004386A patent/MY161237A/en unknown
- 2012-07-02 EA EA201490194A patent/EA030465B1/ru not_active IP Right Cessation
- 2012-07-02 UA UAA201314209A patent/UA114178C2/uk unknown
- 2012-07-02 WO PCT/US2012/045199 patent/WO2013006532A1/en active Application Filing
- 2012-07-02 BR BR112013033940A patent/BR112013033940A2/pt not_active IP Right Cessation
- 2012-07-02 PE PE2013002911A patent/PE20141381A1/es active IP Right Grant
- 2012-07-02 EP EP12735408.2A patent/EP2726074B1/en active Active
- 2012-07-02 MX MX2013015370A patent/MX359406B/es active IP Right Grant
- 2012-07-02 KR KR1020137034740A patent/KR20140040770A/ko active IP Right Grant
- 2012-07-02 ES ES12735408.2T patent/ES2676180T3/es active Active
- 2012-07-02 CA CA2840754A patent/CA2840754A1/en not_active Abandoned
- 2012-07-02 AU AU2012279117A patent/AU2012279117A1/en not_active Abandoned
- 2012-07-02 CN CN201280032544.5A patent/CN103635189B/zh not_active Expired - Fee Related
- 2012-07-02 US US14/124,753 patent/US9271988B2/en active Active
- 2012-07-02 JP JP2014519218A patent/JP5832647B2/ja not_active Expired - Fee Related
-
2013
- 2013-12-06 TN TNP2013000508A patent/TN2013000508A1/fr unknown
- 2013-12-09 IL IL229876A patent/IL229876B/en active IP Right Grant
- 2013-12-09 ZA ZA2013/09241A patent/ZA201309241B/en unknown
- 2013-12-20 GT GT201300320A patent/GT201300320A/es unknown
- 2013-12-20 CO CO13297787A patent/CO6842016A2/es unknown
- 2013-12-26 MA MA36616A patent/MA35210B1/fr unknown
- 2013-12-31 CL CL2013003805A patent/CL2013003805A1/es unknown
-
2015
- 2015-08-17 JP JP2015160531A patent/JP2016027043A/ja active Pending
-
2016
- 2016-01-22 US US15/003,860 patent/US10010552B2/en active Active
- 2016-04-08 AU AU2016202213A patent/AU2016202213A1/en not_active Abandoned
-
2017
- 2017-09-21 AU AU2017232162A patent/AU2017232162B2/en not_active Ceased
Also Published As
Publication number | Publication date |
---|---|
MX2013015370A (es) | 2014-02-11 |
AU2017232162A1 (en) | 2017-10-12 |
BR112013033940A2 (pt) | 2017-02-14 |
ZA201309241B (en) | 2014-08-27 |
AU2017232162B2 (en) | 2019-03-07 |
MX359406B (es) | 2018-09-27 |
ES2676180T3 (es) | 2018-07-17 |
EP2726074A1 (en) | 2014-05-07 |
EP2726074B1 (en) | 2018-04-04 |
MY161237A (en) | 2017-04-14 |
AU2016202213A1 (en) | 2016-05-05 |
UA114178C2 (uk) | 2017-05-10 |
EA030465B1 (ru) | 2018-08-31 |
MA35210B1 (fr) | 2014-06-02 |
WO2013006532A1 (en) | 2013-01-10 |
US20140107114A1 (en) | 2014-04-17 |
EA201490194A1 (ru) | 2014-04-30 |
CL2013003805A1 (es) | 2014-08-08 |
CN103635189A (zh) | 2014-03-12 |
CN103635189B (zh) | 2016-05-04 |
KR20140040770A (ko) | 2014-04-03 |
TN2013000508A1 (en) | 2015-03-30 |
IL229876B (en) | 2018-10-31 |
US9271988B2 (en) | 2016-03-01 |
CO6842016A2 (es) | 2014-01-20 |
JP2016027043A (ja) | 2016-02-18 |
JP2014518279A (ja) | 2014-07-28 |
CA2840754A1 (en) | 2013-01-10 |
US10010552B2 (en) | 2018-07-03 |
JP5832647B2 (ja) | 2015-12-16 |
AU2012279117A1 (en) | 2014-01-09 |
GT201300320A (es) | 2016-03-01 |
US20160136171A1 (en) | 2016-05-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PE20141381A1 (es) | Terapia de combinacion que comprende un inhibidor de cdk4/6 y un inhibidor de pi3k para el uso en el tratamiento de cancer | |
CL2012000772A1 (es) | Compuestos derivados de hetorociclos carboxamidicos sustituidos, antagonista ar; composición farmacéutica que los comprende; y uso en el tratamiento del cáncer de próstata. | |
CL2016001231A1 (es) | Compuestos de inhibidor de autotaxina | |
PH12018502535A1 (en) | Substituted carbonucleoside derivatives useful as anticancer agents | |
CO6630103A2 (es) | Fitocanabinoides en el tratamiento de cáncer | |
PH12017500070A1 (en) | Methods of treating cancer using tigit inhibitors and anti-cancer agents | |
MX2017013613A (es) | Neoepitodos de cancer. | |
CL2007002994A1 (es) | Compuestos derivados heterociclicos que contienen sulfamoilo, inhibidores de hsp90; composicion farmaceutica; y uso para el tratamiento del cancer, tal como cancer de mama, de colon y prostata, entre otros. | |
CL2011000454A1 (es) | Compuestos derivados de picolinamida, inhibidores de quinasa pim, asociada a tumorigenesis; composicion farmaceutica que los comprende; y su uso en el tratamiento del cancer. | |
CL2016001082A1 (es) | Proceso para la síntesis de un inhibidor de indolamina 2,3-dioxigenasa | |
CR20150368A (es) | Inhibidores de histona desmetilasa | |
BR112015011756A2 (pt) | inibidores da glutamase e métodos de uso | |
ECSP099724A (es) | Uso de inhibidores de piridopirimidinona de pi3k-alfa en el tratamiento del cáncer | |
CL2016001604A1 (es) | “compuestos derivados de pirazolo[1,5-a]piridina, inhibidores de quinasas axl y c-met; composición farmacéutica que los comprende; y su uso en el tratamiento del cáncer”. pct | |
CA2900335C (en) | Synthetic analogs of epipolythiodioxopiperazines and uses thereof | |
CL2009000545A1 (es) | Uso de un antagonista de c-met y un antagonista de her para el tratamiento de cancer. | |
AR078824A1 (es) | Compuesto de cabazitaxel y sus usos | |
CL2012000324A1 (es) | Compuestos derivados de benciimidazol sustituido con un grupo pirazol sustituido, inhibidor de quinasa fgfr; composicion farmaceutica que los comprende; y su uso en el tratamiento del cancer. | |
CR10995A (es) | Inhibidores de la actividad de akt | |
CL2012000163A1 (es) | Compuestos derivados de quinazolina o pirido[2,3-d]pirimidina, inhibidores de la autofagia; composicion farmaceutica; y su uso para el tratamiento del cancer, pancreatitis, neurodegeneracion, entre otras. | |
CL2008003846A1 (es) | Uso de compuestos derivados de 1,2,4-triazolo condensado con heterociclos, los cuales actuan como ligados del receptor de androgeno (ar); compuestos; proceso de preparacion; composicion farmaceutica y el uso de dichos compuestos para el tratamiento del cancer de prostata. | |
CL2008002097A1 (es) | Compuestos derivados de heterociclos condensados sustituidos, inhibidores de cinasa de fosfatidil-inositol-3; composicion farmaceutica; y uso en el tratamiento del cancer. | |
EA201171367A1 (ru) | Винилиндазолильные соединения | |
CL2008002369A1 (es) | Compuestos derivados de piridin-3-il-oxipiridin-2-il-amino, inhibidores de alk5; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto en el tratamiento del cancer. | |
UY33866A (es) | Terapia anticancer |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FG | Grant, registration |